Get the Stockscreener App
38.27
5.28%
1.92
Apogee Therapeutics Inc stock is traded at $38.27, with a volume of 644.59K.
It is up +5.28% in the last 24 hours and down -3.36% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$36.35
Open:
$36.56
24h Volume:
644.59K
Relative Volume:
0.76
Market Cap:
$1.76B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-13.90
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
+2.63%
1M Performance:
-3.36%
6M Performance:
+10.77%
1Y Performance:
-19.97%
1-Day Range:
$36.42
$38.88
1-Week Range:
$35.57
$38.88
52-Week Range:
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
38.27 | 2.20B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating - MSN
Apogee Therapeutics (NASDAQ:APGE) Given "Outperform" Rating at Wedbush - MarketBeat
Apogee Therapeutics Faces Supply Chain Risks Amid Geopolitical Tensions and Regulatory Challenges - MSN
Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors - MSN
Apogee Therapeutics (APGE) Is Up 5.9% After Strong APG777 Phase 2 Data and Accelerated Plans - uk.finance.yahoo.com
Apogee Therapeutics Reports Promising Trial Results and Strong Cash Position - TipRanks
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Apogee Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Apogee Therapeutics Q2 2025: A Catalyst-Driven Path to Re-Rating - AInvest
Apogee Therapeutics Q2 Earnings Report: Net Loss of $66.1M, Cash Reserves at $621.2M - AInvest
Apogee Enterprises, Inc. shares fall 2.12% intraday after Apogee Therapeutics, Inc. reported second quarter 2025 financial results. - AInvest
Apogee Therapeutics stock holds steady as Goldman Sachs reiterates rating - Investing.com
Apogee Therapeutics reports Q2 net loss ($66.1M) vs ($33.816M) last year - TipRanks
Apogee Therapeutics' APG777: A Pathway to Redefining Atopic Dermatitis Treatment and Long-Term Value Creation - AInvest
Apogee Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Apogee Therapeutics: A High-Potential Biotech Play in Atopic Dermatitis with Best-in-Class Dosing Advantages and Clear Path to Value Creation - AInvest
Apogee Therapeutics provides pipeline progress and reports second quarter 2025 financial results - MarketScreener
Apogee Therapeutics Provides Pipeline Progress And Reports Second Quarter 2025 Financial Results - TradingView
Apogee Therapeutics, Inc. SEC 10-Q Report - TradingView
Apogee Therapeutics Q2 Net Loss Widens - MarketScreener
Apogee Therapeutics Q2 2025 Financial Results and Pipeline Progress - TradingView
Breakthrough: Apogee's New Atopic Dermatitis Drug Achieves 71% Efficacy with 6-Month Dosing Potential - Stock Titan
Apogee Therapeutics APGE Q2 2025 Earnings Preview Upside Potential Hinges on Strategic Partnerships - AInvest
Apogee Therapeutics CMO Carl Dambkowski Sells Shares - TradingView
This Apogee Therapeutics Insider Increased Their Holding In The Last Year - 富途牛牛
Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? - Yahoo Finance
What are the latest earnings results for Apogee Therapeutics Inc.Outstanding capital returns - Jammu Links News
When is Apogee Therapeutics Inc. stock expected to show significant growthDouble or triple returns - Jammu Links News
Is Apogee Therapeutics Inc. a growth stock or a value stockFastest-growing stock picks - Jammu Links News
What is the risk reward ratio of investing in Apogee Therapeutics Inc. stockAchieve consistent profits with proven methods - Jammu Links News
How many analysts rate Apogee Therapeutics Inc. as a “Buy”Maximize your returns with expert insights - Jammu Links News
Is Apogee Therapeutics Inc. a good long term investmentInvest smarter with expert stock picks - Jammu Links News
Should I hold or sell Apogee Therapeutics Inc. stock in 2025Free Stock Selection - Jammu Links News
Is it the right time to buy Apogee Therapeutics Inc. stockAchieve consistent double-digit growth rates - Jammu Links News
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
How volatile is Apogee Therapeutics Inc. stock compared to the marketChart Pattern Updates For Fast Growth - Jammu Links News
What’s next for Apogee Therapeutics Inc. stock priceTop Performing Stock Insights Released Daily - metal.it
11 Best Future Stocks to Buy Now - Insider Monkey
Published on: 2025-07-30 23:15:33 - metal.it
Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma - MSN
Earnings visualization tools for Apogee Therapeutics Inc.Earnings Impact and Stock Reaction Analysis - Newser
Multi Factor Analysis Ranks Apogee Therapeutics Inc. as Strong BuyIntraday Trend Analysis for Fast Gains Released - metal.it
Order Book Volume Tilts Bullish on Apogee Therapeutics Inc.Trade Ready Stock Watch for Short Term Published - metal.it
Is Apogee Therapeutics Inc. stock overvalued or undervaluedFind the best stocks for sustainable growth - Jammu Links News
What makes Apogee Therapeutics Inc. stock price move sharplySolid Return Trade Selections - Newser
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apogee Therapeutics Inc Stock (APGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Jul 02 '25 |
Option Exercise |
22.86 |
7,365 |
168,364 |
249,088 |
| Dambkowski Carl | Chief Medical Officer |
Jul 02 '25 |
Sale |
45.09 |
10,090 |
454,954 |
238,998 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):